256840.KQ
BNC Korea Co., Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 2,620.00
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 91.2B | 95.9B | 89.2B | 81.0B | 42.3B |
| Cost of Revenue | 59.1B | 56.5B | 47.5B | 45.0B | 27.0B |
| Gross Profit | 32.0B | 39.4B | 41.7B | 36.0B | 15.3B |
| Operating Expenses | |||||
| R&D Expense | 5.7B | 5.1B | 2.7B | 5.0B | 5.4B |
| SG&A Expense | 29.8B | 12.2B | 8.9B | 7.6B | 19.5B |
| General & Admin Expense | 20.1B | 2.7B | 2.8B | 3.1B | 3.2B |
| Selling & Marketing Expense | 2.3B | 9.5B | 6.0B | 4.6B | 7.8B |
| Other Expenses | 4.3B | 20.3B | 19.5B | 12.6B | 12.3B |
| Total Operating Expenses | 37.9B | 37.6B | 31.0B | 25.2B | 24.9B |
| Cost and Expenses | 97.1B | 94.2B | 78.5B | 70.2B | 52.4B |
| Operating Income (EBIT) | (5.9B) | 1.7B | 10.7B | 10.8B | (10.1B) |
| Non-Operating | |||||
| Interest Income | 2.5B | 2.7B | 2.8B | 3.5B | 2.2B |
| Interest Expense | 783.1M | 629.9M | 334.4M | 679.7M | 1.9B |
| Net Interest Income | 1.7B | 2.1B | 2.5B | 2.8B | 313.8M |
| Other Non-Op Income/Expense | 2.4B | 2.6B | 4.9B | 11.7B | (35.8B) |
| Non-Operating Income (excl Interest) | (786.0M) | (3.2B) | (5.3B) | (7.6B) | 33.9B |
| EBT (Pre-Tax Income) | (3.5B) | 4.3B | 15.7B | 17.7B | (45.9B) |
| Income Tax Expense | 2.8B | 2.3B | 2.4B | (8.4B) | (1.3B) |
| Bottom Line | |||||
| Net Income | (4.7B) | 2.8B | 13.3B | 25.7B | (44.7B) |
| Earnings from Cont. Ops | (6.4B) | 2.0B | 13.3B | 26.1B | (44.5B) |
| Earnings from Discont. Ops | — | — | (220.0K) | — | — |
| Bottom Line Net Income | (4.7B) | 2.8B | 13.3B | 25.7B | (44.7B) |
| Per Share | |||||
| Basic EPS | (₩74) | ₩45 | ₩199 | ₩388 | (₩716) |
| Diluted EPS | (₩74) | ₩45 | ₩198 | ₩334 | (₩711) |
| Revenue Per Share | ₩1,333 | ₩1,535 | ₩1,338 | ₩1,224 | ₩678 |
| Shares | |||||
| Basic Shares Outstanding | 68.4M | 62.5M | 66.7M | 66.2M | 62.4M |
| Diluted Shares Outstanding | 68.4M | 62.5M | 66.8M | 67.5M | 62.9M |
| Profitability Metrics | |||||
| EBITDA | 7.4B | 16.3B | 25.3B | 26.5B | (38.8B) |
| D&A | 12.1B | 11.4B | 9.3B | 8.1B | 5.1B |
| EBIT | (4.7B) | 5.0B | 16.0B | 18.4B | (43.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026